Similarly, insurance companies would not be required to cover access to the investigational product.
The measure also provides protections for the physician, stating that a state regulatory authority cannot take action against a physician’s license “based solely on a physician’s recommendation to an eligible patient regarding or prescribing for or treatment with an investigational drug, biological product, or device.”
The language of the ballot measure passed the state House on March 4 and state Senate on April 15.